Literature DB >> 10741859

Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.

W M Prodinger1.   

Abstract

Cellular receptors for complement C3 fragments deposited on antigens are important bricks in the wall defending against microbial pathogens. The part of complement receptor type 2 (CR2; CD21) deals with enhancing humoral immune responses and with long-term trapping of C3d-coated antigen by follicular dendritic cells. CR2 is also pivotal for Epstein-Barr virus (EBV) infection. Here, the current understanding, how CR2 interacts with its ligands C3d, EBV, and CD23 is summarized. The potential to target CR2 for clinical therapy or immunization purposes are discussed.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10741859     DOI： 10.1007/BF02790402

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   4.505


  52 in total

Review 1.  The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity.

Authors:  D T Fearon; R H Carter
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

Review 2.  Activation of B lymphocytes: integrating signals from CD19, CD22 and Fc gamma RIIb1.

Authors:  G M Doody; P W Dempsey; D T Fearon
Journal:  Curr Opin Immunol       Date:  1996-06       Impact factor: 7.486

3.  X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2.

Authors:  B Nagar; R G Jones; R J Diefenbach; D E Isenman; J M Rini
Journal:  Science       Date:  1998-05-22       Impact factor: 47.728

Review 4.  The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity.

Authors:  T F Tedder; M Inaoki; S Sato
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

5.  Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

Authors:  J Tanner; J Weis; D Fearon; Y Whang; E Kieff
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

6.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).

Authors:  M D Moore; R G DiScipio; N R Cooper; G R Nemerow
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

8.  Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen.

Authors:  J M Ahearn; M B Fischer; D Croix; S Goerg; M Ma; J Xia; X Zhou; R G Howard; T L Rothstein; M C Carroll
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

9.  Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.

Authors:  G J Hoffman; S G Lazarowitz; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.

Authors:  A K Matsumoto; D R Martin; R H Carter; L B Klickstein; J M Ahearn; D T Fearon
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307
View more
  3 in total

1.  Synovial biology and T cells in rheumatoid arthritis.

Authors:  Chinh N Tran; Steven K Lundy; David A Fox
Journal:  Pathophysiology       Date:  2005-10

Review 2.  Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.

Authors:  Charles S Via
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

3.  Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer-peptide conjugates.

Authors:  Hui Ding; Wolfgang M Prodinger; Jindrich Kopecek
Journal:  Biomacromolecules       Date:  2006-11       Impact factor: 6.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.